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Abstract
Background: Clinical practice guidelines provide an evidence-based approach to managing single chronic 
conditions, but their applicability to multiple conditions has been actively debated. Incorporating patient-pref-
erence recommendations and involving consumers in guideline development may enhance their applicability, 
but further understanding is needed. Objectives: To assess guidelines that include recommendations for comor-
bid conditions to determine the extent to which they incorporate patient-preference recommendations; 
use consumer-engagement processes during development, and, if so, whether these processes produce more 
patient-preference recommendations; and meet standard quality criteria, particularly in relation to stakeholder 
involvement. Design: A review of Australian guidelines published from 2006 to 2014 that incorporated recom-
mendations for managing comorbid conditions in primary care. Document analysis of guidelines examined the 
presence of patient-preference recommendations and the consumer-engagement processes used. The Appraisal 
of Guidelines for Research and Evaluation instrument was used to assess guideline quality. Results: Thirteen 
guidelines were reviewed. Twelve included at least one core patient-preference recommendation. Ten used 
consumer-engagement processes, including participation in development groups (seven guidelines) and review-
ing drafts (ten guidelines). More extensive consumer engagement was generally linked to greater incorporation 
of patient-preference recommendations. Overall quality of guidelines was mixed, particularly in relation to 
stakeholder involvement. Conclusions: Guidelines do incorporate some patient-preference recommendations, 
but more explicit acknowledgement is required. Consumer-engagement processes used during guideline devel-
opment have the potential to assist in identifying patient preferences, but further research is needed. Clarification 
of the consumer role and investment in consumer training may strengthen these processes.
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Introduction
Clinical practice guidelines targeting specific long-term 
conditions provide an evidence-based approach to treat-
ment and management and can lead to improved patient 
care [1]. However, the ability of guidelines to support 
complex care regimes for patients with multiple long-
term conditions is the subject of some debate [2–6]. The 
use of multiple disease-specific guidelines for individual 
patients is impractical and potentially hazardous [2–5]. 
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Alternative approaches to addressing multiple conditions 
using clinical practice guidelines have been proposed 
and considered [4,7]. These include the development 
of meta-guidelines, which address common clusters of 
co-occurring conditions [7] and greater cross-referenc-
ing between guidelines that are available electronically 
[4]. Some single-condition-specific guidelines include 
recommendations addressing comorbid conditions [3]; 
but the extent to which these guidelines also consider 
patient preferences is unclear.
While the debate about the adaption of clinical guide-
lines continues, a strong theme in the literature is the 
need to foster a patient-centred approach to the man-
agement of multimorbidities and take greater account 
of what patients want and value [8–11]. Patient prefer-
ences – “the desirability of a health-related outcome, process 
or treatment choice” [10] – are considered important for 
the management of multiple and competing health 
conditions as the patient’s focus is shifted from disease-
specific goals to more global cross-disease outcomes, 
such as maintenance of physical function, symptom 
relief and quality of life [12,13]. In essence, some rec-
ommendations may be acceptable to most patients, but 
others may be “preference-sensitive” and dependent on 
the patient’s views about outcome, process or choice 
[10]. Researchers argue that incorporating patient 
preferences may mitigate the common criticism that 
guidelines developed to address single conditions are 
created for the “average patient” and do not acknowl-
edge the complexity of individuals’ circumstances and 
preferences [8,14].
Krahn and Naglie [10] argue that the identification 
and incorporation of patient preferences in guideline 
development and implementation may improve the 
patient-centeredness of clinical practice guidelines. 
They suggest that obtaining consumer input during 
guideline development may provide the foundation 
for greater systematic attention to patient preferences 
and support for patient decision-making in clinical 
consultations [10,15,16]. Strategies to engage consum-
ers in guideline development include providing drafts 
for feedback, involving consumers in guideline-devel-
opment groups, conducting surveys of consumers or 
running consumer focus groups or workshops parallel 
to the clinical guideline development groups [9,17–19]. 
Some of these approaches have been criticized for being 
passive or “tokenistic” [18,19], but broader evidence 
assessing their impact on guideline development is lim-
ited, with the exception of a recent study by Tong et al. 
[16], which found that active consumer engagement led 
to the identification of patient-centred recommenda-
tions not flagged by health professionals.
The widely used Appraisal of Guidelines for Research 
and Evaluation (AGREE) Instrument [20] acknowledges 
the importance of consumer input by way of an item 
assessing whether the views and preferences of the tar-
get population (patients, public, etc.) have been sought. 
In  Australia, for clinical practice guidelines to receive 
approval from the National Health and Medical Research 
Council (NHMRC) [21], they must “be developed by a 
multidisciplinary group that includes relevant experts, end users 
and consumers affected by the clinical practice guideline”. While 
consumer engagement is strongly advocated, it is unclear 
how such engagement takes place or whether it leads 
to greater inclusion of patient- preference recommenda-
tions in clinical guidelines. More broadly, the extent to 
which clinical practice guidelines encourage patient-
centred care through the inclusion of patient preferences 
also requires further investigation.
Objectives
The objectives of this study were to review clinical 
practice guidelines that include recommendations for 
comorbid conditions to determine the extent to which 
they: (1) incorporate patient-preference recommenda-
tions; (2) use consumer-engagement processes in their 
development phase; and (3) meet standard criteria for 
guideline quality, particularly in relation to the stake-
holder-involvement processes; and to consider whether 
consumer-engagement processes in guideline develop-
ment result in greater integration of patient-preference 
recommendations.
Methods
Inclusion criteria
The study examined Australian clinical practice guide-
lines developed to support single chronic conditions, but 
which included recommendations for comorbid condi-
tions (i.e. medical conditions additional to the index 
condition [22]).
All guidelines developed to support the National 
Health Priority areas were included:  cardiovascular 
health; stroke; cancer (colorectal, lung, breast and 
prostate); diabetes; depression; chronic kidney disease; 
asthma and chronic obstructive pulmonary disease; and 
arthritis and musculoskeletal conditions [23]. Additional 
selection criteria included: application in primary care 
settings; and applied to people aged 18 years and over. 
Guidelines are updated approximately every 6 years; 
therefore the search, which began in 2012, focused 
on guidelines published between 2006 and 2012. The 
search was later extended to include publications up to 
January 2014.
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Search strategy
Ovid MEDLINE, Web of Science (ISI), Embase, Cinahl, 
PsycINFO, Cochrane and PubMed, were searched using 
the terms: “guideline”, “Australia”, and “primary care”. 
Additional searches were conducted on Australian web-
sites, including the Department of Health, NHMRC, 
National Institute of Clinical Studies, Royal Australian 
College of General Practitioners and relevant non-profit 
organization websites. The Medical Journal of Australia 
and the Internal Medicine Journal, key journals publish-
ing clinical guidelines, were also searched.
Study selection
Figure 1 summarizes the guideline selection process. In 
all, 4,866 citations were identified: 4,835 of these were 
excluded, based on title and summary. The full text of 
31 guidelines was reviewed. Eighteen were excluded 
because they: did not provide recommendations for 
comorbid conditions; focused on prevention and detec-
tion; addressed out-of-scope conditions; targeted young 
people; were not applicable to primary care; or were out-
dated versions of an included guideline. Clinical updates 
or addenda were assessed in conjunction with the origi-
nal guideline. Thirteen guidelines were included in the 
final analysis.
Data analysis
Data analysis was conducted in three stages in accor-
dance with the three main aims of the study. Stages 1 
and 2 involved document analysis and Stage 3 involved 
a quality assessment using AGREE II. Ethics approval 
was not required as all data were drawn from published 
materials available in the public domain.
Stage 1
Document analysis of the guidelines was conducted to 
identify recommendations that incorporated patient 
preferences. Clinical practice guidelines vary in com-
plexity and size, ranging in length from ten to several 
hundred pages and frequently provide a list of core rec-
ommendations or essential points, which are then further 
explained throughout the document by “supporting 
evidence statements”. The core recommendations and 
supporting evidence statements were analysed to identify 
recommendations that focused on patient preferences.
Analysis was directed by the framework approach [24], 
which involved five steps (familiarization; identifying a 
thematic framework; indexing; charting; and mapping 
and interpretation). Detailed review of the guidelines 
ensured familiarity with content and enabled the iden-
tification of key themes that aligned with the notion of 
patient preferences. An index framework that defined 
key themes including and consistent with patient prefer-
ences (e.g. “actively involved” recommended patients be 
engaged, involved or given the opportunity to participate 
in the decision-making process) was developed and used 
to code content. Relevant passages from each guideline 
were extracted in accordance with the themes and placed 
in charts to assist with mapping and interpreting the data.
Three guidelines provided recommendations and evi-
dence statements for both children and adults [25–27]. 
Recommendations and evidence statements that focused 
only on children were excluded from the analysis.
Stage 2
Document analysis using the framework approach was 
also conducted to assess the consumer-engagement pro-
cesses used during guideline development. Explanation 
437 duplicates removed 
4,835 excluded on title/abstract 
Not a guideline (4,152) 
Condition not included (547) 
Not Australian (100) 
For people aged <18 years (19) 
Not based in primary care (17) 
13 included in final report 
18 excluded on full analysis 
For prevention not management (4) 
Condition not included (4) 
For people aged <18 years (1) 
Not based in primary care (1) 
Outdated or duplicate version of 
included guideline (6) 
No comorbid recommendations (2) 
4,866 references screened on title and
abstract
31 references selected for full analysis
AGREE II
Analysis
Framework
Analysis
5,303 references identified by search 
1.  Database (5,281) 
2.  Online search (22) 
Identification 
Screening 
Eligibility 
Include
Figure 1 Search strategy. AGREE II, Appraisal of Guidelines for Research and Evaluation II.
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of guideline-development processes, including consumer 
engagement, was typically described at the beginning or 
end of the guideline, or occasionally in a separate report. 
All of this material was reviewed. A thematic framework 
was developed from key themes identified in the docu-
ment analysis and from the literature (e.g. “training and 
education”). This framework was used to code guide-
line content.
Stage 3
An assessment of guideline quality was conducted using 
the AGREE II instrument [20]. AGREE II is a validated 
tool that assesses guideline quality according to 23 items 
listed under six domains: scope and purpose; stakeholder 
involvement; rigour of development; clarity of presenta-
tion; applicability; and editorial independence [5]. For 
each domain, questions are scored on a 7-point scale 
from 7 (strongly agree) to 1 (strongly disagree). An overall 
domain score was calculated from the sum of individual 
items standardized as a percentage for each domain [20]. 
Guidelines were assessed as “good quality” [3] if they 
scored above 60% on all of the AGREE II domains. Two 
reviewers (C.E.Y. and K.S.B.) independently scored each 
guideline. The AGREE II concordance calculator [28] 
confirmed an acceptable level of agreement between the 
reviewers.
In line with the study aims to examine consumer-
engagement processes, particular attention was paid 
to the stakeholder domain in the AGREE II, which 
includes three items: 1) guideline development includes 
individuals from all relevant professional groups; 2) 
the views and preferences of the target population (e.g. 
patients, public) have been sought; and 3) the target 
users of the guideline are clearly defined [20].
Results
Thirteen guidelines met the inclusion criteria: four 
guidelines for cardiovascular health [29–32]; one guide-
line for stroke [33]; one guideline for prostate cancer 
[34]; two guidelines for diabetes mellitus [25,26]; two 
guidelines for musculoskeletal health [35,36]; two 
guidelines for respiratory conditions [27,37]; and one 
guideline targeted multiple chronic conditions focusing 
on the prevention and management of chronic kidney 
disease for people with type 2 diabetes [38]. Eleven 
guidelines were developed by non-profit organizations 
[25–27,29–34,37,38] and two guidelines by the Royal 
Australian College of General Practitioners [35,36]. 
Five guidelines were approved by the NHMRC 
[25,33,35,36,38]. The guidelines ranged in length from 
19 to 288 pages.
Incorporating patient preferences
Across the 13 guidelines, a total of 1,076 core rec-
ommendations were reviewed, of which 49 (4.5%) 
were identified as patient-preference-related recom-
mendations (see Table 1). The number of total core 
recommendations ranged from 18 to 335 for individual 
guidelines and the number of core patient-preference-
related recommendations ranged from 0 to 16 (0–12.2% 
of the total core recommendations). A further 108 
statements, directing clinicians to consider patient pref-
erences, were identified in the supporting evidence 
statements (range 0–25).
Examination of both the guideline recommendations 
and supporting evidence statements revealed four key 
themes: patient preferences; care plans; actively involved; 
and risks and benefits (Table 1). General introductory 
comments or “blanket statements” [8] emphasizing the 
need to consider individuals’ views were also identified.
Twelve guidelines explicitly asked for patient prefer-
ences to be considered by the clinician in relation to 
treatment, interventions, or outcomes [25–27,29–37]. 
For example, the guideline on type 1 diabetes stated: 
“Choice of device should be made on the basis of ease of use, 
patient preference/suitability and overall cost” [25].
Care plans, also referred to as management, action 
and treatment plans, were highlighted by all but two 
guidelines [32,38] as a means of working collabora-
tively with patients to identify their preferences and 
goals for care. Care plans were the most frequently 
flagged core patient-preference-related recommenda-
tions (range 0–13) and were also commonly discussed 
in the supporting evidence statements (range 2–6) (see 
Table 1). For example, the guideline for rheumatoid 
arthritis stated the following: “General practitioners should 
aim to engage patients with RA [rheumatoid arthritis] in indi-
vidualised care plans that include treatment goals and objective 
measures of disease” [35].
Seven guidelines [25–27,32,33,35,37] called for 
patients to be actively involved or engaged in decision-
making and as a member of the healthcare team, as 
illustrated by this example from the guideline for type 2 
diabetes: “Encourage patients to participate and take an active 
role in the management of their diabetes” [26].
Five guidelines [27,31,33,34,36] suggested outlin-
ing the risks and benefits of recommended treatments 
to enable patients to make an informed decision based 
on their treatment preferences, as demonstrated by the 
guideline for prostate cancer: “Toxicities should be con-
sidered in the context of what is important to each individual 
patient, as for some patients impairment of sexual function 
may have a significant impact on their quality of life and over-
all adjustment, as well as affecting adversely those close to 
them” [34].
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Eleven guidelines provided blanket statements [25–
27,30–36,38]. These were statements provided at the 
beginning of the document, instructing clinicians that 
all recommendations should be individualized to con-
sider the needs, preferences and context of each patient. 
For example, the chronic kidney disease in type 2 dia-
betes guideline, the only guideline that did not include 
any core patient-preference-related recommendations, 
began with the following overarching statement: “This 
document is a general guide to appropriate practice, to be fol-
lowed subject to the clinician’s judgement and the patient’s 
preference in each individual case. The guidelines are designed 
to provide information to assist decision-making and are based 
on the best evidence available at the time of development” [38].
Guideline quality
The AGREE II domain scores for each guideline are 
presented in Table 2. Across all guidelines, the appli-
cability domain (i.e. “has the guideline outlined potential 
barriers and facilitators to its implementation in practice, strat-
egies to improve uptake, and resource implications”) received 
the lowest domain scores, while clarity of presentation 
(i.e. “are the recommendations specific and easily identifiable, 
and are the various options clearly presented”) received the 
highest domain scores [20]. Clarity of presentation was 
the only domain for which all guidelines scored above 
60%.
The five guidelines approved by the NHMRC consist-
ently scored higher across all domains [25,33,35,36,38]. 
Within this group, the guideline for stroke was the only 
guideline to score above 60% in all domains [33].
Of particular interest was the stakeholder involvement 
domain. Six guidelines scored above 60% for this domain 
[25,33–36,38]. Closer examination of the individual 
items within this domain revealed that 11 guidelines 
scored better (average between the two reviewers above 
4.2 (60%) on a 7-point rating scale) for the first item: 
“included individuals from all relevant professional groups 
in the development group” [25,27,29,30,32–38]; and the 
third item: “clearly defined target users” [25–27,30–36,38]. 
In contrast, only four guidelines scored above 60% 
[25,33,34,38] on the second item “the views and pref-
erences of the target population (patients, public, etc.) have 
been sought”. To score highly on this item, guideline 
developers needed to outline the strategies used to gain 
consumer perspectives, report the outcomes of this 
process and describe how this was used to inform the 
guideline.
Consumer-engagement processes
The thematic framework developed for this phase of the 
analysis covered four key themes: consumer involvement Ta
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in the development group; clarification of this role; 
provision of drafts for public review; and training and 
education. Across the guidelines, only two methods 
of engagement were reported: involving consumer 
representative(s) in guideline-development groups; and 
providing drafts for public review. Seven guidelines used 
both methods [25,33–38], three provided drafts for pub-
lic review only [29,31,32], and three did not report their 
methods of engagement [26,27,30] (see Table 3).
Most guideline-development groups included one or 
two consumer representatives recruited from relevant 
non-profit organizations, with the exception of the 
guideline for stroke [33], which included three con-
sumers, and the guideline for chronic kidney disease 
in type 2 diabetes [38], which included five consum-
ers, one for each of the five smaller expert advisory 
groups forming the guideline-development group (see 
Table 3). None of the guidelines reported training and 
education of consumers. Seven guidelines reported 
the broad role of the development group [25,33–38]; 
only one provided a specific explanation of the con-
sumer’s role [38]. “Consumer representatives were selected 
and appointed by Diabetes Australia for each EAG [Expert 
Advisory Group] to ensure the consideration of people with 
type 2 diabetes with respect to their acceptability of the pro-
posed guideline recommendations” [38].
Ten guidelines provided drafts for public review 
[25,29,31–38], but the extent to which this engaged 
consumers was not always possible to ascertain. Four 
guidelines provided an explanation of the results of 
the public-review processes, outlining how comments 
were incorporated or changes made [25,33,34,38]. The 
comments addressed a range of issues including guide-
line structure, chapter size, editing, and clarification of 
recommendations and supporting evidence statements. 
Six guidelines did not clarify the extent or nature of 
the feedback process [29,31,32,35–37]. For example, 
the guideline on osteoarthritis stated: “Feedback collected 
from the survey and independent submissions were collated and 
addressed by the Working Group” [36].
The study also considered whether consumer-
engagement processes in guideline development resulted 
in greater integration of patient preferences. There was 
some suggestion that more extensive use of consumer-
engagement processes (i.e. both provision of drafts for 
public review and inclusion of consumers in the devel-
opment group) was associated with greater incorporation 
of patient-preference recommendations. Six of the 
seven guidelines that produced the greatest proportion 
of core patient-preference recommendations (as shown 
in Table 1) used both consumer-engagement methods 
[25,33–37]. However, the guideline that reported the 
most comprehensive consumer-engagement processes 
(i.e. provided a specific explanation of the consumers’ Ta
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role, included five consumers in the development group, 
and stated how the public review feedback was incorpo-
rated) [38] did not explicitly include recommendations 
targeting patient preferences. Rather a blanket statement 
was provided at the beginning of the document calling 
for patient preferences to be considered when applying 
the guideline to individual patients.
Discussion
All 13 of the reviewed guidelines acknowledged patient 
preferences, either explicitly or indirectly through 
related themes [25–27,29–38], but their location and 
prominence varied, appearing as core recommendations, 
supporting evidence statements and/or blanket state-
ments. Ten guidelines reported some form of consumer 
engagement during their development [25,29,31–38]. 
The guidelines that employed the most extensive con-
sumer-engagement processes (e.g. both provision of 
drafts for public review and inclusion of consumers in 
the development group) were among those with the 
greatest proportion of patient-preference recommenda-
tions [25,33–38]. Overall, the quality of guidelines was 
mixed; the lack of evidence of strategies to incorporate 
the views and preferences of consumers saw many fall 
short on stakeholder involvement.
Quantifying the extent to which guidelines incorpo-
rate patient preferences was not always straightforward, 
as some recommendations and supporting evidence 
statements were less explicit in their request that patient 
preferences be considered. Similarly, patient preferences 
were more frequently presented in supporting evidence 
statements than in core recommendations. Presenting 
patient preference information in supporting evidence 
statements may undermine the potential of guidelines to 
support a more systematic discussion of patient prefer-
ences in primary care as it risks this information being 
overlooked by time-poor clinicians. In practice, clini-
cians and patients frequently identify differences in their 
preferences, priorities and goals for care when manag-
ing multiple conditions; if not discussed and worked 
through, these differences can lead patients to disengage 
from clinical advice [39]. Clearer and more frequent flag-
ging of patient-preference-related recommendations in 
guidelines is needed to draw attention to patient prefer-
ences in clinical consultations. Consistently identifying 
these recommendations and facilitating their discussion 
is one way in which guidelines might support a more 
systematic approach to patient-centred care [10,16].
Overall, more extensive use of consumer-engage-
ment processes in guideline development was linked 
to a greater proportion of core patient-preference rec-
ommendations; however, closer consideration of the Ta
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consumer-engagement processes used across the guide-
lines highlights shortfalls in practice. Ten guidelines 
engaged consumers in public-review processes [25,29,31–
38]. These typically ‘passive’ methods have been criticized 
for limiting consumers’ ability to actively engage and pro-
vide valuable input [16,19,40]. Seven guidelines engaged 
consumers in development groups [25,33–38], but there 
was little evidence of the provision of training or specific 
role descriptions for consumers.
Research suggests that unless guideline developers 
provide consumers participating in development groups 
with education and training, a clear explanation of their 
role, and sufficient support (e.g. more than one con-
sumer representative), their involvement is likely to be 
tokenistic and relatively ineffective [17–19]. In support, 
Tong et al. [16] found that, when adequately assisted and 
engaged, consumers were able to contribute meaning-
fully to guideline development by identifying topics and 
outcomes (e.g. day-to-day management and overall ill-
ness experience) not identified by health professionals. 
This experiential input is the cornerstone of consumer 
engagement: it extends the clinicians’ focus from disease 
to incorporate the patients’ social context, experiences, 
and feelings [14]. In short, without effectively engaging 
consumers, guideline developers risk producing guide-
lines that may not fully address the topics and outcomes 
of importance to patients, particularly those experienc-
ing multiple conditions [14,16,19].
Our findings, like those of Vitry and Zhang [6], 
demonstrate the role of NHMRC standards in contrib-
uting to the development of higher quality guidelines in 
Australia. Currently, the inclusion of a consumer repre-
sentative in guideline development groups is a NHMRC 
standard [21], but our findings are consistent with other 
research suggesting this approach may be of limited 
value when used in isolation and without proper support 
of consumers [18,19]. Further clarification of consumer-
engagement processes and their purpose could be driven 
by a revision of the NHMRC standards for clinical prac-
tice guidelines [21].
The limitations of this study need to be acknowl-
edged. An extensive search was conducted, but it is 
possible that eligible guidelines were missed as, unlike 
other countries, such as the UK [41], there is no central-
ized guideline-development organization in Australia. 
The analysis conducted for this study was based on 
all publicly available information including published 
guidelines and their supporting documents. It is possi-
ble that more extensive consumer-engagement processes 
were conducted, but not reported. Since standardized 
quality-assessment practices, such as AGREE II, rely on 
published materials, there is a clear need for guideline 
developers to provide full information that accurately 
reports all elements of the development process.
Conclusion
Clinical practice guidelines appear to be taking impor-
tant steps towards supporting clinicians and patients 
through the incorporation of patient-preference rec-
ommendations, but there is scope for more explicit 
acknowledgement. Consumer-engagement processes 
used to develop guidelines have the potential to con-
tribute to the identification of patient preferences, but 
further research is needed to investigate the contribu-
tion and impacts of these processes. Clarification of the 
consumer role and investment in consumer training may 
help to strengthen these processes and further support a 
systems-based approach to patient-centred care for peo-
ple with multiple chronic conditions.
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